MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keag273

Медицинская библиотека · Rheumatology (Oxford, England) · 2026

CAR-T as a salvage treatment in polyrefractory RA.

Lidar Merav, David Paula, Jacoby Elad, Shapira-Frommer Ronnie, Itzhaki Orit, Eshet Yael, Eshed Iris, Marcus Ronit, Shimoni Avichai, Yerushalmi Ronit, Danylesko Ivetta, Tov Noga Shem, Slobodin Gleb, Kaly Lisa, Samara Reem, Avigdor Abraham, Rimar Doron

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To evaluate the utility of CD19-directed chimeric antigen receptor T cell (CAR-T) therapy in patients with persistent inflammatory refractory RA (PIRRA), who failed ≥5 biologic/targeted synthetic DMARDs classes.

METHODS

Three women with long-standing, seropositive PIRRA received autologous anti-CD19 CAR-T therapy with CD 28 co-stimulation. After lymphodepletion with fludarabine and cyclophosphamide, an infusion of 0.6-1 × 106 CAR-T cells/kg was administered. Clinical, laboratory, imaging and histological outcomes were assessed up to 18 months.

RESULTS

Median age was 54 years (range 39-68), and median disease duration was 14 ± 3.1 years. All developed grade 3 cytokine release syndrome (CRS), and one developed grade 4 ICANS. No long-term toxicities were observed, except for hypogammaglobulinemia, that has not required replacement therapy. Within 3 months, two patients achieved remission, and one had low disease activity. At the last follow-up, two remained in drug-free remission, and one attained low disease activity with abatacept and MTX. HAQ-DI scores improved from severe disability to near-normal. RF and ACPA titres markedly declined. Furthermore, imaging demonstrated resolution of synovitis and clearance of CD19+B cells from the synovium establishing histological remission.

CONCLUSION

CD19 CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRRA. Despite significant acute toxicities, recovery was complete and long-term safety was favourable. These findings suggest that CAR-T may provide a transformative benefit in severe RA, warranting controlled clinical trials.

Для цитирования: Lidar Merav, David Paula, Jacoby Elad, Shapira-Frommer Ronnie, Itzhaki Orit, Eshet Yael, Eshed Iris, Marcus Ronit, Shimoni Avichai, Yerushalmi Ronit, Danylesko Ivetta, Tov Noga Shem, Slobodin Gleb, Kaly Lisa, Samara Reem, Avigdor Abraham, Rimar Doron. CAR-T as a salvage treatment in polyrefractory RA.. Rheumatology (Oxford, England). 2026. DOI: 10.1093/rheumatology/keag273.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.